- cafead   Sep 12, 2023 at 11:02: AM
via Sandoz on Monday signed a development and commercialization contract with Samsung Bioepis for SB17, the latter’s biosimilar to Johnson & Johnson’s Stelara (ustekinumab).
article source
article source